Ascendis Pharma A/S (ASND)

Ascendis Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	572.82	616.04	559.54	392.16	444.77	446.27
Short-Term Investments	-	-	-	7.28	290.69	235.8
Cash & Short-Term Investments	572.82	616.04	559.54	399.44	735.46	682.06
Cash Growth	10.60%	10.10%	40.08%	-45.69%	7.83%	-5.11%
Accounts Receivable	178.68	141.33	166.28	35.87	11.91	2.2
Other Receivables	17.93	16.36	11.16	19.9	13.72	20.99
Total Trade Receivables	196.61	157.7	177.44	55.77	25.63	23.19
Inventory	314.34	301.53	295.61	208.93	130.67	75.41
Other Current Assets	38.57	33.72	28.27	38.58	31.72	25.23
Total Current Assets	1,122	1,109	1,061	702.72	923.47	805.89
Net Property, Plant & Equipment	135.92	146.48	98.71	110.63	129.1	126.05
Other Intangible Assets	3.69	3.71	4.03	4.42	4.83	5.27
Long-Term Investments	23.56	32.53	13.58	5.69	30.42	145.91
Other Long-Term Assets	717.77	10.87	2.32	2.13	1.92	1.81
Total Assets	2,003	1,303	1,179	825.59	1,090	1,085

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	78.59	90.66	96.39	94.57	101.03	59.42
Current Portion of Long-Term Debt	510.56	486.53	491.54	421.27	11.63	7
Current Portion of Leases	-	-	-	-	13.79	-
Unearned Revenue	5.36	4.94	0.94	1.18	-	2.6
Other Current Liabilities	532.25	487.26	319	219.49	44.82	31.34
Total Current Liabilities	1,127	1,069	907.86	736.51	171.27	100.36
Long-Term Debt	386.11	385.25	365.08	223	387.56	97.97
Long-Term Leases	-	-	-	-	95.4	-
Other Long-Term Liabilities	2.44	10.75	12.26	11.78	172.16	2.96
Total Long-Term Liabilities	388.54	396	377.34	234.78	655.12	100.93
Total Liabilities	1,515	1,465	1,285	971.28	826.39	201.29

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	8.38	8.32	8.15	7.75	7.68	7.65
Retained Earnings	479.59	-171.14	-113.86	-153.45	255.67	875.99
Shareholders' Equity	487.97	-162.82	-105.71	-145.7	263.35	883.64
Total Liabilities & Equity	2,003	1,303	1,179	825.59	1,090	1,085

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	896.66	871.79	856.62	644.27	508.38	104.96
Net Cash (Debt)	-323.84	-255.75	-297.07	-244.83	227.08	577.1
Net Cash Growth	-	-	-	-	-60.65%	-7.93%
Net Cash Per Share	-5.17	-4.22	-5.13	-4.35	4.05	10.54
Book Value	487.97	-162.82	-105.71	-145.7	263.35	883.64
Book Value Per Share	7.80	-2.69	-1.83	-2.59	4.70	16.13
Tangible Book Value	484.28	-166.53	-109.73	-150.12	258.52	878.36
Tangible Book Value Per Share	7.74	-2.75	-1.90	-2.67	4.61	16.04

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: May 7, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error